Linda Bhatt

Linda Bhatt examines pharmacogenomic factors influencing response and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Her research has characterized germline genetic variants that modulate TKI pharmacokinetics and on-target toxicity. She has identified somatic and germline determinants of acquired resistance beyond the T790M mutation in EGFR-mutant lung cancer. Her translational work has helped define the interplay between tumor genomics and germline pharmacogenomics in determining outcomes from targeted therapy.